‘Monday morning quarterbacks’ question EMA rigor, says unreimbursed CEO
This article was originally published in Scrip
Jame Bianco, Cell Therapeutics' CEO, says there is a "fundamental issue" with the European Medicines Agency's drug approval process and the subsequent wrangling with Europe's pricing and reimbursement bodies, he said. His comments come after Pixuvri (pixantrone) was rejected by NICE, England's health technology appraisal institute (scripintelligence.com, 11 April 2013).
You may also be interested in...
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.